Dernières nouvelles
Information non disponible
Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion
Article de revueCurr Oncol, 30 (2), 2023.
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
Article de revueLeukemia, 34 (2), 2020.
Evaluation of eligibility and recruitment in breast cancer clinical trials
Article de revueBreast, 23 (4), 2014.
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients
Article de revueAnn Pharmacother, 48 (4), 2014.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
Article de revueBlood, 121 (9), 2013.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Article de revueLancet Oncol, 12 (11), 2011.
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
Article de revueJ Clin Oncol, 29 (25), 2011.